Indications
Waylivra is indicated as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.
Composition
- Active substance
- volanesorsen sodium
- International name (INN)
- volanesorsen
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Waylivra
- Active substance
- volanesorsen sodium
- ATC code
- C10AX18
- Therapeutic area
- Hyperlipoproteinemia Type I
- Marketing authorisation holder